Effectiveness of Opioids-Adjuvant Analgesics Combinations for Pediatric Cancer Pain: A Systematic Review

https://doi.org/10.22146/jmpf.100789

Ulfa Filliana(1*), Susi Ari Kristina(2), Bekti Meilani Nurcahya(3)

(1) Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Wahid Hasyim, Semarang, Central Java
(2) Department of Pharmaceutics, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta
(3) Division of Clinical Pharmacy in Pediatric, RSUP Dr. Kariadi Semarang, Central Java
(*) Corresponding Author

Abstract


Background: The pediatric cancer was reported that they got worst pain and 40% weren’t managed well. The impact of untreated cancer pain is low quality of life and poor pain experienced. Therefore, it is important to know the best analgesic for improving the clinical outcome of pain.

Objectives: This study aims to determine the effectiveness of using opioid combined with adjuvant analgesics based on WHO analgesic ladder in pediatric cancer pain.

Methods: PubMed and Science Direct were searched for randomized controlled trials and retrospective studies by the keyword’s “opioid”, “adjuvant analgesic”, “pediatric”, “cancer” within 2014-2024. The primary outcome was using Faces Pain Scale, or visual analog scale (VAS), or numerical rating scale (NRS).

Results: A result of 556 studies were reviewed. After further inspection of collected studies, only 5 studies achieved all inclusion criteria. The final studies consist of two prospective studies with randomized trial and three retrospective studies. Combination gabapentin or pregabalin as adjuvant analgesic with opioids was better reduced pain intensity and less adverse events than other combinations.

Conclusion: This study supports the increased effectiveness of analgesic opioid combined with adjuvant analgesics, compared with single opioid, in the treatment of pediatric cancer pain. Further study inspires researchers to conduct studies using the randomized trial method and continue meta-analysis study especially in pediatric population and developing countries.


Keywords


cancer pain; pediatric; opioid; adjuvant analgesic; effectiveness

Full Text:

PDF


References

  1. Siegel DA, King JB, Lupo PJ, et al. Counts, incidence rates, and trends of pediatric cancer in the United States, 2003-2019. J Natl Cancer Inst. 2023;115(11):1337-1354. doi:10.1093/jnci/djad115
  2. WienPJ ZB. Cochrane Library Cochrane Database of Systematic Reviews Opioids for cancer-related pain in children and adolescents (Review). Published online 2020. doi:10.1002/14651858.CD012564.pub2
  3. Tutelman PR, Chambers CT, Stinson JN, et al. Pain in Children with Cancer Prevalence, Characteristics, and Parent Management. Clinical Journal of Pain. 2018;34(3):198-206. doi:10.1097/AJP.0000000000000531
  4. Duran J, Bravo L, Torres V, et al. Quality of Life and Pain Experienced by Children and Adolescents with Cancer at Home Following Discharge from the Hospital. J Pediatr Hematol Oncol. 2020;42(1):46-52. doi:10.1097/MPH.0000000000001605
  5. Jain P, Gulati S, Seth R, Bakhshi S, Toteja GS, Pandey RM. Vincristine-induced Neuropathy in Childhood ALL (Acute Lymphoblastic Leukemia) Survivors. https://doi.org/101177/0883073813491829. 2013;29(7):932-937. doi:10.1177/0883073813491829
  6. Tay N, Laakso EL, Schweitzer D, Endersby R, Vetter I, Starobova H. Chemotherapy-induced peripheral neuropathy in children and adolescent cancer patients. Front Mol Biosci.Frontiers Media S.A. 2022;9. doi:10.3389/fmolb.2022.1015746
  7. Smith EML, Kuisell C, Cho Y, et al. Characteristics and patterns of pediatric chemotherapy-induced peripheral neuropathy: A systematic review. Cancer Treat Res Commun.Elsevier Ltd. 2021;28. doi:10.1016/j.ctarc.2021.100420
  8. Cunico D, Rossi A, Verdesca M, Principi N, Esposito S. Pain Management in Children Admitted to the Emergency Room: A Narrative Review. Pharmaceuticals.Multidisciplinary Digital Publishing Institute (MDPI). 2023;16(8). doi:10.3390/ph16081178
  9. Fallon M, Dierberger K, Leng M, et al. An international, open-label, randomised trial comparing a two-step approach versus the standard three-step approach of the WHO analgesic ladder in patients with cancer. Annals of Oncology. 2022;33(12):1296-1303. doi:10.1016/j.annonc.2022.08.083
  10. Van Den Beuken-Van Everdingen MHJ, Hochstenbach LMJ, Joosten EAJ, Tjan-Heijnen VCG, Janssen DJA. Update on Prevalence of Pain in Patients with Cancer: Systematic Review and Meta-Analysis. J Pain Symptom Manage.Elsevier Inc. 2016;51(6):1070-1090.e9. doi:10.1016/j.jpainsymman.2015.12.340
  11. Leal EL, Santos PCJL, Gonçalves TS, et al. Evaluations of NSAIDs and Opioids as Analgesics in Pediatric Oncology. Future Pharmacology. 2023;3(4):916-925. doi:10.3390/futurepharmacol3040055
  12. Courade M, Bertrand A, Guerrini-Rousseau L, et al. Low-dose ketamine adjuvant treatment for refractory pain in children, adolescents and young adults with cancer: a pilot study. BMJ Support Palliat Care. 2019;12(e5):E656-E663. doi:10.1136/bmjspcare-2018-001739
  13. Othman AH, Mohamad MF, Sayed HAR. Transdermal fentanyl for cancer pain management in opioid-naive pediatric cancer patients. Pain Medicine (United States). 2016;17(7):1329-1336. doi:10.1093/pm/pnw004
  14. Voepel-Lewis T, Malviya S, Tait AR. Inappropriate opioid dosing and prescribing for children: An unintended consequence of the clinical pain score? JAMA Pediatr.American Medical Association. 2017;171(1):5-6. doi:10.1001/jamapediatrics.2016.2839
  15. Chung CP, Callahan ST, Cooper WO, et al. Outpatient Opioid Prescriptions for Children and Opioid-Related Adverse Events.
  16. Portenoy RK, Ahmed E, Keilson Y. Cancer Pain Management: Role of Adjuvant Analgesics (Coanalgesics).; 2022. Accessed June 10, 2024. https://www.uptodate.com/
  17. Bao H, Wu Z, Wang Q, et al. The efficacy of gabapentin combined with opioids for neuropathic cancer pain: a meta-analysis. Transl Cancer Res. 2021;10(2):633-644. doi:10.21037/TCR-20-2692
  18. PRISMA 2020 checklist — PRISMA statement. Accessed November 7, 2025. https://www.prisma-statement.org/prisma-2020-checklist
  19. Haroun R, Wood JN, Sikandar S. Mechanisms of cancer pain. Frontiers in Pain Research.Frontiers Media S.A. 2022;3. doi:10.3389/fpain.2022.1030899
  20. Edwards HL, Mulvey MR, Bennett MI. Cancer-related neuropathic pain. Cancers (Basel).MDPI AG. 2019;11(3). doi:10.3390/cancers11030373
  21. Yoon SY, Oh J. Neuropathic cancer pain: Prevalence, pathophysiology, and management. Korean Journal of Internal Medicine.Korean Association of Internal Medicine. 2018;33(6):1058-1069. doi:10.3904/kjim.2018.162
  22. Bakır M, Rumeli Ş, Pire A. Multimodal Analgesia in Pediatric Cancer Pain Management: A Retrospective Single-Center Study. Cureus. Published online September 14, 2023. doi:10.7759/cureus.45223
  23. Caraceni A, Shkodra M. Cancer pain assessment and classification. Cancers (Basel). 2019;11(4). doi:10.3390/cancers11040510
  24. Ghobrial HZ, Shaker EH, Hanna HZ. Effectiveness of Multimodal Preemptive Analgesia in Major Pediatric Abdominal Cancer Surgery. Vol 23.; 2019. www.apicareonline.com
  25. Wang X, Yi Y, Tang D, et al. Gabapentin as an Adjuvant Therapy for Prevention of Acute Phantom-Limb Pain in Pediatric Patients Undergoing Amputation for Malignant Bone Tumors: A Prospective Double-Blind Randomized Controlled Trial. J Pain Symptom Manage. 2018;55(3):721-727. doi:10.1016/j.jpainsymman.2017.11.029
  26. Revuri VR, Moody K, Lewis V, Mejia R, Harrison DJ, Ahmad AH. Pain and Analgesia in Children with Cancer after Hemipelvectomy: A Retrospective Analysis. Children. 2022;9(2). doi:10.3390/children9020237
  27. Fallon M, Giusti R, Aielli F, et al. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines †. ESMO Updated Clinical Practice Guidelines. 2018;29:iv166-iv191. doi:10.1093/annonc/mdy152
  28. Swarm RA, Youngwerth JM, Agne JL, et al. Adult Cancer Pain, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025;23(7). doi:10.6004/JNCCN.2025.0032
  29. Palat G, Algotsson C, Rayala S, et al. The use of methadone in pediatric cancer pain - A retrospective study from a Governmental Cancer Center in India. Indian J Palliat Care. 2021;27(1):133-138. doi:10.4103/IJPC.IJPC_109_20
  30. Gai N, Naser · Basem, Hanley J, Peliowski A, Hayes J, Kazuyoshi Aoyama ·. A practical guide to acute pain management in children. J Anesth. 2020;34:421-433. doi:10.1007/s00540-020-02767-x
  31. Schuster M, Bayer O, Heid F, Laufenberg-Feldmann R. Opioid rotation in cancer pain treatment - A systematic review. Dtsch Arztebl Int. 2018;115(9):135-142. doi:10.3238/arztebl.2018.0135
  32. Mawatari H, Shinjo T, Morita T, Kohara H, Yomiya K. Revision of Pharmacological Treatment Recommendations for Cancer Pain: Clinical Guidelines from the Japanese Society of Palliative Medicine. J Palliat Med. 2022;25(7):1095-1114. doi:10.1089/JPM.2021.0438/ASSET/IMAGES/JPM.2021.0438_FIGURE1.JPG
  33. Sitepu ES, Puspitasari AW, Azmi NU, Sari LN. Evaluation of Potential Drug Interaction of Analgesic in Cancer Patient Receiving Palliative Care in Dharmais Cancer Hospital ARTICLE HISTORY. Pharmaceutical Sciences and Research. 2020;7(1):1-8.
  34. Meaadi J, Obara I, Eldabe S, Nazar H. The safety and efficacy of gabapentinoids in the management of neuropathic pain: a systematic review with meta-analysis of randomised controlled trials. Int J Clin Pharm.Springer Science and Business Media Deutschland GmbH. 2023;45(3):556-565. doi:10.1007/s11096-022-01528-y
  35. Goodman CW, Brett AS. A Clinical Overview of Off-label Use of Gabapentinoid Drugs. JAMA Intern Med.American Medical Association. 2019;179(5):695-701. doi:10.1001/jamainternmed.2019.0086
  36. Derry S MR. Cochrane Database of Systematic Reviews Pregabalin for neuropathic pain in adults (Review). Published online 2019. doi:10.1002/14651858.CD007076.pub3
  37. Sleigh J, Harvey M, Voss L, Denny B. Ketamine - more mechanisms of action than just NMDA blockade. Trends in Anaesthesia and Critical Care.Churchill Livingstone. 2014;4(2-3):76-81. doi:10.1016/j.tacc.2014.03.002
  38. Ma X, Yan J, Jiang H. Application of Ketamine in Pain Management and the Underlying Mechanism. Pain Res Manag.Hindawi Limited. 2023;2023. doi:10.1155/2023/1928969
  39. Gibbons K, DeMonbrun A, Beckman EJ, et al. Continuous Lidocaine Infusions to Manage Opioid-Refractory Pain in a Series of Cancer Patients in a Pediatric Hospital. Pediatr Blood Cancer. 2016;63(7):1168-1174. doi:10.1002/pbc.25870
  40. Mestdagh F, Steyaert A, Lavand’homme P. Cancer Pain Management: A Narrative Review of Current Concepts, Strategies, and Techniques. Current Oncology.Multidisciplinary Digital Publishing Institute (MDPI). 2023;30(7):6838-6858. doi:10.3390/curroncol30070500
  41. Corli O, Roberto A, Bennett MI, et al. Nonresponsiveness and Susceptibility of Opioid Side Effects Related to Cancer Patients’ Clinical Characteristics: A Post-Hoc Analysis. Pain Practice. 2018;18(6):748-757. doi:10.1111/papr.12669
  42. Yang Y, Maher DP, Cohen SP. Emerging concepts on the use of ketamine for chronic pain. Expert Rev Clin Pharmacol.Taylor and Francis Ltd. 2020;13(2):135-146. doi:10.1080/17512433.2020.1717947
  43. Jiao J, Fan J, Zhang Y, Chen L. Efficacy and Safety of Ketamine to Treat Cancer Pain in Adult Patients: A Systematic Review. J Pain Symptom Manage. 2024;67(3):e185-e210. doi:10.1016/j.jpainsymman.2023.11.004
  44. Pregabalin Combined With Opioids for Managing Neuropathic Pain in Patients With Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Accessed November 8, 2025. https://www.researchgate.net/publication/388687657
  45. Hall EA, Sauer HE, Habashy C, Anghelescu DL. Methadone for Cancer Pain in Pediatric End-of-Life Care. American Journal of Hospice and Palliative Medicine. 2021;38(8):914-919. doi:10.1177/1049909120963641
  46. Habashy C, Springer E, Hall EA, Anghelescu DL. Methadone for pain management in children with cancer. Pediatric Drugs.Springer International Publishing. 2018;20(5):409-416. doi:10.1007/s40272-018-0304-2
  47. Hanna V, Senderovich H. Methadone in Pain Management: A Systematic Review. J Pain. 2021;22(3):233-245. doi:10.1016/J.JPAIN.2020.04.004
  48. Rawat PS, Jaiswal A, Khurana A, Bhatti JS, Navik U. Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management. Biomedicine and Pharmacotherapy.Elsevier Masson s.r.l. 2021;139. doi:10.1016/j.biopha.2021.111708



DOI: https://doi.org/10.22146/jmpf.100789

Article Metrics

Abstract views : 0 | views : 0

Refbacks

  • There are currently no refbacks.


Copyright (c) 2026 JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice)

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

©Jurnal Manajemen dan Pelayanan Farmasi
Faculty of Pharmacy
Universitas Gadjah Mada
Creative Commons License
View My Stats